Navigation Links
SemBioSys signs option agreement for safflower-produced food ingredient
Date:1/29/2008

r the production of chymosin in plants at significantly lower costs.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys announces 2007 third quarter results
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys updates Apo AI development program
4. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
7. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
8. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
9. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
10. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
11. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised ... molecular diagnostics industry. BCC Research reveals in its new report that the market drivers ... and a growing need for better diagnostics as part of a molecular diagnostics trend. ...
(Date:7/1/2015)... 1, 2015 Isagenix International, a leading global ... Gold, three Silver, and three Bronze Stevie® Awards at ... Chicago this month.The American ... awards program in the U.S. "Winning ... in developing leaders, cultivating talent, creating a unified team, ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable ... devices now have an operator control device that will increase healthcare worker safety ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... (Nasdaq: MNKD ) today announced that Matthew ... President and Chief Financial Officer,effective April 21, 2008. ... Chief Operating Officer, and will serve on MannKind,s,executive ... retirement of Dick Anderson, who has now transitioned ...
... (Nasdaq: KOSN ) presented data on its ... of target,specificity, strong binding affinity and potency, a ... and safety in murine xenograft,and orthotopic models., ... stabilize and/or activate a,number of proteins required for ...
... Laboratories, a national,clinical and anatomic pathology reference laboratory and ... that,company co-founder Carl R. Kjeldsberg, MD, will retire as ... Kjeldsberg has held the position,since 1993 and will continue ... Effective, July 1, 2009, Edward R. Ashwood, MD, ...
Cached Biology Technology:Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4ARUP Laboratories CEO and Co-Founder Announces Retirement 2
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... plate tectonics on Earth; Arctic Ocean,s role in the ... Olduvai Basin lake cycles and survival of early hominins; ... relationship between earthquakes and melting glaciers; monitoring Mt. Etna ... end of the PETM. The GSA TODAY science article ...
... in eastern Australia now have greater access to the ... NSW Department of Primary Industries (DPI). Trials undertaken ... cold storage at temperatures of 2 or 3C can ... 14 to16 days. Cold treatment at these temperatures ...
... declining food prices driven down by unprecedented advances in ... for wheat have tripled and those for maize and rice ... prices will fall soon. On the contrary, economists expect larger ... change and its devastating impacts on agriculture adding greatly to ...
Cached Biology News:December GEOLOGY and GSA TODAY media highlights 2December GEOLOGY and GSA TODAY media highlights 3December GEOLOGY and GSA TODAY media highlights 4December GEOLOGY and GSA TODAY media highlights 5December GEOLOGY and GSA TODAY media highlights 6December GEOLOGY and GSA TODAY media highlights 7December GEOLOGY and GSA TODAY media highlights 8December GEOLOGY and GSA TODAY media highlights 9December GEOLOGY and GSA TODAY media highlights 10Cold treatment opens doors for citrus exports to Japan 2Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers 2
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
PKC (pSer345), phospho-specific...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Biology Products: